NCT04867707

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: University of Missouri-Columbia · Academic / Other
• Sex: All
• Age: 45 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.

Detailed description

Twenty subjects will complete five days of treatment with zanamivir. Baseline measurements will be taken before the initiation of treatment, as well as after the conclusion of the treatment period (i.e., a total of two assessment visits per subject). Assessment visits will include: vitals (such as blood pressure, heart rate), fasting blood work for plasma neuraminidase activity, plasma sialic acid, plasma glucose and plasma insulin, brachial artery FMD, and glycocalyx integrity assessment via Glycocheck.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Zanamivir	5 days of treatment with 10mg zanamivir inhaler BID

Timeline

• Start date: 2021-07-14
• Primary completion: 2024-10-18
• Completion: 2024-10-18
• First posted: 2021-04-30
• Last updated: 2025-04-25
• Results posted: 2025-04-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study